The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease
- 31 December 2003
- journal article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 29 (6) , 613-618
- https://doi.org/10.1016/s1262-3636(07)70077-0
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery diseaseThe American Journal of Cardiology, 2001
- 1. Role of HDL in reverse cholesterol transportAtherosclerosis, 1999
- A comparison of the bioavailability of standard or micronized formulations of fenofibrateCurrent Therapeutic Research, 1993
- Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience)The American Journal of Cardiology, 1992
- Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: The Caerphilly and Speedwell Collaborative Heart Disease StudiesHeart, 1992
- Scavenging for receptorsNature, 1990
- The triglyceride issue: A view from FraminghamAmerican Heart Journal, 1986
- Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research GroupJAMA, 1982
- Biliary and plasma lipids and lipid-lowering chemotherapy Studies with clofibrate, fenofibrate and etofibrate in healthy volunteersAtherosclerosis, 1980
- Risk Factors in Coronary Heart DiseaseAnnals of Internal Medicine, 1964